At the just-concluded ninth China International Import Expo in Shanghai, a range of cutting-edge artificial intelligence medical solutions were unveiled, becoming a main highlight of the expo's medical equipment and healthcare products exhibition area.
AI technology has expanded from imaging assistance to surgical navigation, chronic disease management and intelligent decision-making throughout medical interventions. The CIIE serves as a vital platform for validating AI scenarios, connecting with hospitals and accelerating the technology's transformation.
Roche showcased its innovative solutions developed in collaboration with ecosystem partners at its booth. These solutions integrate AI and digital tools across the entire industrial chain, breaking down data barriers and enhancing precision throughout the diagnostic and treatment process.
Among such innovations is a one-stop AI research tool that leverages Roche's medical insights and partners' digital capabilities to support doctors with intelligent topic selection, literature review and solution generation, thereby boosting research efficiency and accelerating the transformation of research results. Another featured tool is a digital remote patient management system that offers follow-up reminders and disease education, ensuring continuous and accessible home health management for patients.
Incaier, the healthcare arm of Haier Group, showcased six AI-driven scenarios at the expo: AI plus autonomous lab, AI plus low-temperature bioprocessing, AI plus autonomous drug management, AI plus clinical innovation, AI plus proactive health and AI plus biopharmaceutical.
The company also launched its AI strategy, powered by a central "Incaier brain" and forming three industrial intelligence engines continuously transforming capabilities into AI-native products, intelligent entities and digital-physical fusion scenarios. Among these is an AI intelligent platform providing a unified interaction portal for researchers, healthcare professional and patients, with over 450 AI-native applications already developed.
Australian biopharmaceutical company CSL signed an agreement with Peking Union Medical College Hospital at the CIIE to explore using AI in identifying and assisting in the diagnosis of patients suffering from hereditary angioedema, a rare disorder causing recurrent swelling.
A representative from the hospital expressed hope that the collaboration would leverage advanced AI algorithms to support traditional lab testing and expedite the translation of cutting-edge technology into clinical tools, enhancing early diagnosis and screening efficiency for clinicians.
The growing clinical value of AI and the formation of human-machine collaborative medical teams were highlighted in the 2026 China edition of the Future Health Index report released by Philips at the CIIE.
According to the report, 95 percent of Chinese clinical healthcare workers surveyed said that their focus has shifted or will shift toward higher-value clinical work, while 81 percent of Chinese patients surveyed believed that learning to use AI will become an essential skill for health management. Both figures surpassed the global averages of 82 percent and 59 percent, respectively.
The report also noted that 69 percent of Chinese healthcare workers believe that AI helps improve patient health outcomes.
"China is actively integrating AI into medical practice, becoming a leading force in global medical AI applications," Liu Ling, chief regional leader of Philips China, said.
